Skip to main content

Table 2 Clinicopathological features of epithelial ovarian cancer patients of all 12 cases

From: Differences in immune-related gene expressions and tumor-infiltrating lymphocytes according to chemotherapeutic response in ovarian high-grade serous carcinoma

Case

Age

FIGO stage

Pathologic diagnosis

CTx regimen

Follow-up period (mo)

Time of recurrence after CTx (mo)

Response group

Status of survival

1

42

IIIc

HGSC

Carbo-Taxol

15

4

CR

No

2

63

IV

HGSC

Carbo-Taxol

29

8

CR

No

3

79

IIIc

HGSC

Carbo-Taxol

17

4

CR

N/A

4

66

IIIc

HGSC

Carbo-Taxol

29

Progression during CTx

CR

N/A

5

62

IV

HGSC

Carbo-Taxol

10

1

CR

No

6

73

IV

HGSC

Carbo-Taxol

30

Relapse within CTx

CR

Yes

7

64

IIIc

HGSC

Carbo-Taxol

35

No relapse

CS

Yes

8

55

IIIc

HGSC

Carbo-Taxol

51

No relapse

CS

Yes

9

62

IIIc

HGSC

Carbo-Taxol

64

No relapse

CS

Yes

10

69

IIa

HGSC

Carbo-Taxol

39

32

CS

Yes

11

50

IIIc

HGSC

Carbo-Taxol

24

No relapse

CS

Yes

12

49

IV

HGSC

Carbo-Taxol

75

19

CS

Yes

  1. FIGO the International Federation of Gynecology and Obstetrics, HGSC High-grade serous carcinoma, CTx chemotherapy, Carbo-Taxol carboplatin and paclitaxel, mo month, CR chemoresistant, CS chemosensitive, N/A not applicable